Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.47 |
| ▸ | ME2 | P23368 | 1/20 | 0.47 |
| ▸ | ME1 | P48163 | 1/20 | 0.47 |
| ▸ | ME3 | Q16798 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826516 | 1.00 | GRM5 (0.62) | GRM5TSHRTACR1HTTMAPK1 | |
| SCHEMBL2800375 | 0.86 | TACR1 (0.56) | TACR1SLC1A1CYP3A4 | |
| SCHEMBL2800372 | 0.86 | TACR1 (0.56) | TACR1SLC1A1CYP3A4 | |
| SCHEMBL4467696 | 0.85 | GRM5 (0.62) | GRM5TSHRHTTMAPK1ADAMTS5 | |
| SCHEMBL2545138 | 0.82 | TSHR (0.57) | TSHRTACR1NPSR1ALDH1A1POLB | |
| SCHEMBL15084146 | 0.81 | GRM5 (0.58) | GRM5TSHRTACR1HTTMAPK1 | |
| Hydrochloric Acid SCHEMBL2545139 | 0.81 | TSHR (0.56) | TSHRTACR1LMNAALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL2545135 | 0.81 | TSHR (0.56) | TSHRTACR1LMNAALDH1A1POLB | |
| SCHEMBL4334098 | 0.80 | GRM5 (0.54) | GRM5TSHRHTTMAPK1ADAMTS5 | |
| SCHEMBL4334109 | 0.79 | GRM5 (0.53) | GRM5TSHRHTTMAPK1SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883721-B2 | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof | MCGILL UNIVERSITY (CA) | 2014-11-11 | — | — | US | claimed |
| US-20120135918-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2012-05-31 | — | — | US | claimed |
| US-20090069245-A1 | GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2009-03-12 | — | — | US | claimed |
| US-10550377-B2 | Suppression of prostate cancer using a targeted clostridial neurotoxin | IPSEN BIOINNOVATION LIMITED (GB) | 2020-02-04 | — | — | US | disclosed |
| EP-2719392-B1 | Fusion proteins for use in the treatment of acromegaly | IPSEN BIOINNOVATION LTD (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-20190127718-A1 | SUPPRESSION OF CANCER | IPSEN BIOINNOVATION LIMITED (GB) | 2019-05-02 | — | — | US | disclosed |
| EP-3473643-A1 | FUSION PROTEINS FOR USE IN THE TREATEMNT OF CANCER | Ipsen Bioinnovation Limited (GB) | 2019-04-24 | — | — | EP | disclosed |
| EP-2310029-B1 | Fusion proteins for use in the treatment of cancer | IPSEN BIOINNOVATION LTD (GB) | 2019-04-03 | — | — | EP | disclosed |
| US-10240138-B2 | Polypeptides that bind to and inhibit secretion from growth hormone secreting cells | IPSEN BIOINNOVATION LIMITED | 2019-03-26 | — | — | US | disclosed |
| US-10113159-B2 | Suppression of cancer | IPSEN BIOINNOVATION LIMITED (GB) | 2018-10-30 | — | — | US | disclosed |
| EP-3241560-A1 | SUPPRESSION OF CANCER | Ipsen Bioinnovation Limited (GB) | 2017-11-08 | — | — | EP | disclosed |
| US-20110262423-A1 | SUPPRESSION OF CANCER | SYNTAXIN LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| US-20110171191-A1 | SUPPRESSION OF NEUROENDOCRINE DISEASES | SYNTAXIN LIMITED (GB) | 2011-07-14 | — | — | US | disclosed |
| US-20110165137-A1 | SUPPRESSION OF CANCERS | SYNTAXIN LIMITED (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110160135-A1 | SUPPRESSION OF NEUROENDOCRINE DISEASES | SYNTAXIN LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| WO-2010132580-A2 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20090069245-A1 | GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2009-03-12 | — | — | US | disclosed |
| EP-2021015-A2 | GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | The Administrators Of The Tulane Educational Fund (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007127457-A9 | GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | UNIV TULANE (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007127457-A2 | GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135918-A1 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | GHSR, GIPR, GHRHR | GRM5 396/4885TSHR 27/4885TACR1 236/4885 |
| US-20090069245-A1 | GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF | GHSR, GHRHR, GIPR | GRM5 186/4885TSHR 56/4885TACR1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.